Dysbindin genotype and negative symptoms in schizophrenia.
OBJECTIVE
Converging evidence has demonstrated an association between variants in the dysbindin gene (DTNBP1) and schizophrenia. Recently, a DTNBP1 risk haplotype, associated with both schizophrenia and neurocognitive dysfunction, has been identified. Because neurocognitive dysfunction is commonly accompanied by negative symptoms (avolition, alogia, and affective flattening) in schizophrenia, the authors hypothesized that the presence of the risk haplotype would be significantly associated with negative symptoms.


METHODS
The authors tested for an association between a DTNBP1 risk haplotype and a lifetime history of negative symptoms in 181 Caucasian patients with schizophrenia.


RESULTS
A significant association was found between the presence of the risk haplotype and negative symptoms.


CONCLUSIONS
These data suggest that the effect of DTNBP1 genetic variation may be associated with negative symptoms in patients with schizophrenia.
DeRosse
Pamela
P
Department of Psychiatry Research, The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks, NY 11004, USA. pderosse@lij.edu
Funke
Birgit
B
Burdick
Katherine E
KE
Lencz
Todd
T
Ekholm
Jenny M
JM
Kane
John M
JM
Kucherlapati
Raju
R
Malhotra
Anil K
AK
D000328:Adult; D002352:Carrier Proteins / Q000235:genetics*; D039721:Diagnostic and Statistical Manual of Mental Disorders; D000074765:Dysbindin; D049029:Dystrophin-Associated Proteins; D005260:Female; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D006239:Haplotypes / Q000235:genetics*; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D012307:Risk Factors; D012559:Schizophrenia / Q000175:diagnosis* / Q000235:genetics*; D012565:Schizophrenic Psychology; D044465:White People / Q000235:genetics
D002352:Carrier Proteins; C432416:DTNBP1 protein, human; D000074765:Dysbindin; D049029:Dystrophin-Associated Proteins